Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of France based on a 10-year multicentre retrospective collection.
Study Type
OBSERVATIONAL
Enrollment
70
Age of the patients when diagnosed with MPAL
Age in years
Time frame: At inclusion (Day 0)
Sex of the patients when diagnosed with MPAL
Male or female
Time frame: At inclusion (Day 0)
City of the hematology unit in charge of each patient for the treatment of MPAL
Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon or Besançon
Time frame: At inclusion (Day 0)
MPAL rate in the each hematology unit
Rate of MPAL out of the total number of patients diagnosed with acute leukemia in each hematology unit
Time frame: 10 years (01/01/2008-01/01/2018)
Date of MPAL diagnosis for each patient
Time frame: At inclusion (Day 0)
Type of MPAL for each patient
De novo MPAL or secondary to myelodysplasia MPAL
Time frame: At inclusion (Day 0)
Percentage of blood blasts for each patient at diagnosis of MPAL
On the first blood sample analyzed
Time frame: At inclusion (D0)
Percentage of medullar blasts for each patient at diagnosis of MPAL
On the first bone marrow sample analyzed
Time frame: At inclusion (Day 0)
Cytologic characteristics: type of myeloid markers at diagnosis for each patient
Presence or not of myeloid markers generally sought in the diagnosis of acute leukaemias
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At inclusion (Day 0)
Cytologic characteristics: type of B lymphoid markers at diagnosis for each patient
Presence or not of B lymphoid markers generally sought in the diagnosis of acute leukaemias
Time frame: At inclusion (Day 0)
Cytologic characteristics: type of T lymphoid markers
Presence or not of T lymphoid markers generally sought in the diagnosis of acute leukemias
Time frame: At inclusion (D0)
Medullar MPO positivity percentage at diagnosis for each patient
If performed on the bone marrow sample used to confirm the diagnosis
Time frame: At inclusion (Day 0)
Genetic characteristics on the caryotype at diagnosis for each patient
Presence or not of caryotypic abnormalities generally sought in the diagnosis of acute leukemias
Time frame: At inclusion (Day 0)
Genetic characteristics on molecular biology analysis at diagnosis for each patient
Presence or not of molecular biology abnormalities generally sought in the diagnosis of acute leukemias
Time frame: At inclusion (D0)
Classification of biphenotypic acute leukemia (BAL) according to the EGIL 1998 criterias at diagnosis
BAL or not
Time frame: At inclusion (Day 0)
Classification of MPAL according to the WHO 2008 criterias at diagnosis
MPAL or not
Time frame: At inclusion (Day 0)
Type of treatments and dates of the first day of every treatment line for each patient
Myeloid or lymphoid chemotherapy regimen
Time frame: 10 years (01/01/2008-01/01/2018)
Medullar response for every treatments line for each patient
Complete cytological and molecular response or treatment failure
Time frame: 10 years (01/01/2008-01/01/2018)
Treatment including allogenic hematopoietic stem cells transplant (HSCT) (yes or no) with type of conditionning regimen for each patient
High-dose, reduced-intensity or nonmyeloablative conditioning regimens with or without total body irradiation
Time frame: 10 years (01/01/2008-01/01/2018)
HSCT complicated with acute and/or chronic graft-versus-host disease with severity grade and treatments for each patient
Diagnosis of GVHD according to Filipovich criterias (BMT 2005); Severity grade according to Seattle criterias; Type of treatments: steroids, other immunosuppressive agents, extracorporeal photopheresis
Time frame: 10 years (01/01/2008-01/01/2018)
Date of every relapse for each patient
Time frame: 10 years (01/01/2008-01/01/2018)
Date of death if occured
Time frame: 10 years (01/01/2008-01/01/2018)
Cause of death
Secondary to leukemia, treatment or other cause
Time frame: 10 years (01/01/2008-01/01/2018)